| Literature DB >> 33809638 |
Yen-An Lin1,2, Pei-Yi Chu3, Wen-Lung Ma2, Wei-Chung Cheng2,4, Shu-Ting Chan5, Juan-Cheng Yang3, Yang-Chang Wu3,6,7.
Abstract
Surgical wounds are common injuries of skin and tissues and usually become a clinical problem. Until now, various synthetic and natural peptides have been widely explored as potential drug candidates for wound healing. Inhibition of the TNF-α signaling pathway and promotion of angiogenesis are suggested to be involved in their effects. Angiogenesis at the wound site is one of the essential requisites for rapid healing. In the present study, a novel peptide extract derived from the natural source Lates calcarifer, commonly known as sea bass or barramundi, was evaluated for its wound healing property. The specific acidic and enzymatic approaches were employed for producing sea bass extract containing small size peptides (molecular weight ranging from 1 kD to 5 kD). The cytotoxicity of the extract was examined in HaCaT and NIH3T3. After this, the effects of enzyme digested peptide extracts of sea bass on wound healing in mice were investigated. The peptide extracts (660 and 1320 mg/kg/day) and control protein (1320 mg/kg/day) was orally given to the wounded mice, respectively, for 12 days. The surgical method was improved by implanting a silicone ring at the wound site. The ring avoided the contracting effect in murine wounds, making it more closely related to a clinical condition. The results showed promising improvement at the wound site in mice. Sea bass peptide extracts accelerated the wound healing process and enhanced the microvessel formation at the wound site. The remarkable effects of this novel sea bass peptide extract in healing traumatic injuries revealed a new option for developing wound management.Entities:
Keywords: Lates calcarifer; angiogenesis; murine model; wound healing
Year: 2021 PMID: 33809638 PMCID: PMC8002292 DOI: 10.3390/md19030154
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1The procedure of Lates calcarifer-extracted peptide (LCEP) production.
Figure 2Molecular weight distribution of peptide extract derived from sea bass. LC–MS/MS was used to determine the molecular weight and analysis the molecular weight distribution of sea bass peptide extract. (A) 10,000 mass (m/z), (B) 8500 mass (m/z), (C) 5000 mass (m/z), (D) molecular weight distribution of enzymatically extracted peptide (red line) and nonenzymatically extracted peptide (black line).
Figure 3Effects of sea bass peptide extract on cell viability. HaCaT (A) and NIH3T3 (B) cells were treated with Lates calcarifer extract peptide (LCEP) 0, 10, 20, 40 and 80 mg/mL, respectively. Viabilities were determined at 24 h. Data are means ± standard deviation (SD) (n = 9). There is no statistically significant difference between the groups.
Figure 4Schematic diagram of the in vivo study.
Figure 5Effects of oral LCEP treatment on wound healing in murine wound model using splint rings. LCEP and control protein were given daily to mice after the surgery for 12 days. Photos of the wounds were taken from day 0 to day 12 (A). The percentage of the wound area was calculated (B). Area under the curve (AUC) of the wound area were calculated (C). Data are means ± standard deviation (SD) (n = 9). The differences between the treatment groups and the vehicle group were analyzed using one-way ANOVA followed by the post hoc Dunnett’s multiple comparisons test. Significant thresholds were set at *** p < 0.001 (B) and * p < 0.05 (C).
Figure 6Effects of oral LCEP treatment on angiogenesis in murine wound model using splint ring. Immunohistochemistry analysis was applied to investigate the microvessel formation in mice. Mice fed with LCEP for 6 days, 9 days or 12 days, after which they were sacrificed and subjected to CD31 staining in order to evaluate the status of angiogenesis (A). The quantitative data of microvessel density (MVD) were analyzed by CD31 immunohistochemistry staining (brown). Density was analyzed by staining area (mm2) using ImageScope 12.4 (B). Data are means ± standard deviation (SD) (n = 7). The differences between treatment groups and vehicle groups were analyzed using one-way ANOVA followed by the post hoc Dunnett’s multiple comparisons test. Significant thresholds were set at * p < 0.05, ** p < 0.01, and *** p < 0.001.